ClinicalTrials.gg
CompletedNCT01560286Updated Aug 6, 2019Results posted

A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks

A Phase 2 interventional study of BMN 165 (rAvPAL-PEG) in Phenylketonuria, sponsored by BioMarin Pharmaceutical. Completed at 6 sites in United States. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-08-06.

Sponsored by BioMarin Pharmaceutical · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
16 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing pegvaliase in Phenylketonurias — 1 open to participants now, 2 under way, 1 of them phase 3. pegvaliase · Phenylketonurias.

Enrollment
8th of 10
24 · median 39
Started
2012
the only one that year
Phase 2
4 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
10 of 10
BioMarin Pharmaceutical

Among the 10 studies testing pegvaliase in Phenylketonurias, this one is the 8th largest by enrollment, is the only one that started in 2012, is one of 4 in phase 2, and was the 5th registered.

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

Browse Phenylketonurias studies →

Open to participants now

1 of the 10 studies testing pegvaliase in Phenylketonurias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegvaliase

pegvaliase: first FDA approval 2018 (PALYNZIQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 16 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing pegvaliase in Phenylketonurias, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the effect of dosing regimens of multiple subcutaneous (SC) doses of rAvPAL-PEG to induce an early and sustained Phe reduction while decreasing the frequency and severity of hypersensitivity reactions in patients with PKU.

Read the detailed description

The primary rationale for this study is to define an optimal rAvPAL-PEG dose regimen by establishing the therapeutic effect within the shortest time possible time for induction, titration and maintenance phases while reducing the severity and frequency of hypersensitivity reactions that may lead to dose interruptions. It is hypothesized that these goals can be achieved by keeping rAvPAL-PEG doses low when anti-PEG IgM response is predicted to be high and titrating to an efficacious dose once the IgG response to PAL has developed. Further investigation is needed to determine how early and quickly patients can titrate safely to lower blood Phe; therefore, this protocol proposes to assess two Groups using an induction/titration and maintenance schedule with an aim towards establishing the therapeutic effect safety within an optimal period of time.

03

Conditions studied

  • Phenylketonuria

Browse trials for

Keywords

  • PKU
  • Injections
  • PEG-PAL
  • PAL
04

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A diagnosis of PKU, with the following:

    • Current blood Phe concentration of ≥ 600 µmol/L at Screening.
    • Average blood Phe concentration of ≥ 600 µmol/L over the past 6 months, using available data.
    • Naïve to prior treatment with rAvPAL-PEG.
  2. Evidence that the patient is a non responder to Kuvan® treatment (ie, 4 weeks of treatment with 20 mg/kg/day of Kuvan, insufficient response per investigator determination, unsuitable for Kuvan® per Investigator determination, and treatment end date ≥ 2 days prior to Day 1 [ie, first dose]). Patients who have had a previous response to Kuvan® treatment but are not currently taking Kuvan® because of noncompliance and have been off treatment for ≥ 4 months prior to Screening are eligible for participation.
  3. Willing and able to provide written, signed after the nature of the study has been explained and prior to any research-related procedures. In the case of participants under the age of 18 or participants who have been deemed mentally unable to provide informed consent, a parent or legal guardian may provide written informed consent (and, if required, the patient will provide written assent).
  4. Willing and able to comply with all study procedures.
  5. Between the ages of 16 and 70 years, inclusive.
  6. Females of must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening, or who have had total hysterectomy.
  7. Sexually active patients must be willing to use an acceptable method of while participating in the study.
  8. Maintained a stable diet with no significant modifications during the 4 weeks preceding the administration of study drug and willing to continue with the diet while on study so as to avoid potential variability of response due to variations in dietary intake.
  9. In generally good health as evidenced by physical examination, clinical laboratory evaluations (hematology, chemistry, and urinalysis), and (ECG) at Screening.

Exclusion criteria

Exclusion Criteria:

  1. Use of any product or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
  2. Use of any medication that is intended to treat PKU, including use of large amino acids, within 2 days prior to the administration of study drug.
  3. Use or planned use of any injectable drugs containing PEG (other than rAvPAL-PEG), including Depo-Provera, within 3 months prior to Screening and during study participation.
  4. A prior reaction that included systemic symptoms (eg, respiratory or gastrointestinal problems, hypotension, angioedema, anaphylaxis) to a PEG containing product. Patients with a prior systemic reaction of generalized rash may be eligible for participation per the discretion of the Principal Investigator in consultation with the Sponsor's Medical Officer.
  5. Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) or to breastfeed at any time during the study.
  6. Concurrent disease or condition that would interfere with study participation or safety (eg, history or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease).
  7. Any condition that, in the view of the PI, places the patient at high risk of poor treatment compliance or of not completing the study.
  8. (ALT) concentration > 2 times the .
  9. Creatinine > 1.5 times the upper limit of normal.
  10. A positive test for (HIV) antibody, surface antigen and antibody.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Group 1

    4-8 week induction of rAvPAL-PEG at 2.5 mg, followed by titration to maintenance dose

    Biological: BMN 165 (rAvPAL-PEG)

Interventions

  • Subcutaneous injection of rAvPAL-PEG administered from 1 time up to 5 times per week between 2.5mg up to a maximum of 375mg for 24 weeks.

    Also known as: Recombinant Anabaena variabilis phenylalanine ammonia lyase

06

What researchers measure

Primary outcomes

  1. Blood Phenylalanine Concentration

    All patients will have their plasma Phenylalanine (Phe) assessed. Please note that "Pharmacokinetics Sub-study" was not performed, and thus no results are available.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Number of Participants With Study Drug Related Adverse Events

    Time frame: Minimum Weekly Assessment of Injection Sites, Vital Signs and Adverse Events. Other Safety Assessments will be performed at other intervals (below):

  2. Percentage of Participants With Positive Anti-PAL Immunoglobulin G [IgG]

    Antibody Positivity

    Time frame: Baseline, Week 24

  3. Trough Concentration of BMN 165

    PK assessment from pre-dose blood draw.

    Time frame: Week 1, Week 24

  4. Percentage of Participants With Positive Anti-PEG IgG

    Antibody Positivity

    Time frame: Baseline, Week 24

  5. Percentage of Participants With Positive PAL-IgM

    Antibody Positivity

    Time frame: Baseline, Week 24

  6. Percentage of Participants With Positive Anti-PEG-IgM

    Antibody positivity

    Time frame: Baseline, Week 24

  7. Percentage of Participants With Positive Neutralizing Antibodies [Nab]

    Antibody positivity

    Time frame: Baseline, Week 24

  8. Percentage of Participants With Positive Anti-PAL-IgE Antibodies

    Antibody positivity

    Time frame: Baseline, Week 24

  9. Percentage of Participants With Positive Anti-PAL-PEG IgE Antibodies

    Antibody positivity

    Time frame: Baseline, Week 24

07

Results

Posted Feb 27, 2019

Participant flow

Participant flow — Overall Study
MilestoneBMN 165 (rAvPAL-PEG)
Started24
Completed24
Not completed0

Outcome measures

PrimaryBlood Phenylalanine Concentration

All patients will have their plasma Phenylalanine (Phe) assessed. Please note that "Pharmacokinetics Sub-study" was not performed, and thus no results are available.

Time frame:
Baseline, Week 24
Reported as:
Mean · umol/L
Blood Phenylalanine Concentration
umol/LrAvPAL-PEG
Baseline1168.8 ± 290.98
Week 24617.6 ± 529.28
SecondaryNumber of Participants With Study Drug Related Adverse Events
Time frame:
Minimum Weekly Assessment of Injection Sites, Vital Signs and Adverse Events. Other Safety Assessments will be performed at other intervals (below):
Reported as:
Count of participants · Participants
Number of Participants With Study Drug Related Adverse Events
ParticipantsrAvPAL-PEG
Number of Participants With Study Drug Related Adverse Events23
SecondaryPercentage of Participants With Positive Anti-PAL Immunoglobulin G [IgG]

Antibody Positivity

Time frame:
Baseline, Week 24
Reported as:
Number · percentage
Percentage of Participants With Positive Anti-PAL Immunoglobulin G [IgG]
percentagerAvPAL-PEG
Baseline4.3
Week 2495.5
SecondaryTrough Concentration of BMN 165

PK assessment from pre-dose blood draw.

Time frame:
Week 1, Week 24
Reported as:
Mean · ng/mL
Trough Concentration of BMN 165
ng/mLrAvPAL-PEG
Week 1 Day 10.2 ± 1.09
Week 242341.1 ± 4768.28
SecondaryPercentage of Participants With Positive Anti-PEG IgG

Antibody Positivity

Time frame:
Baseline, Week 24
Reported as:
Number · percentage
Percentage of Participants With Positive Anti-PEG IgG
percentagerAvPAL-PEG
Baseline26.1
Week 2422.7
SecondaryPercentage of Participants With Positive PAL-IgM

Antibody Positivity

Time frame:
Baseline, Week 24
Reported as:
Number · percentage
Percentage of Participants With Positive PAL-IgM
percentagerAvPAL-PEG
Baseline34.8
Week 2490.9
SecondaryPercentage of Participants With Positive Anti-PEG-IgM

Antibody positivity

Time frame:
Baseline, Week 24
Reported as:
Number · percentage
Percentage of Participants With Positive Anti-PEG-IgM
percentagerAvPAL-PEG
Baseline4.3
Week 249.1
SecondaryPercentage of Participants With Positive Neutralizing Antibodies [Nab]

Antibody positivity

Time frame:
Baseline, Week 24
Reported as:
Number · percentage
Percentage of Participants With Positive Neutralizing Antibodies [Nab]
percentagerAvPAL-PEG
Baseline0
Week 2427.3
SecondaryPercentage of Participants With Positive Anti-PAL-IgE Antibodies

Antibody positivity

Time frame:
Baseline, Week 24
Reported as:
Number · percentage
Percentage of Participants With Positive Anti-PAL-IgE Antibodies
percentagerAvPAL-PEG
Baseline0
Week 240
SecondaryPercentage of Participants With Positive Anti-PAL-PEG IgE Antibodies

Antibody positivity

Time frame:
Baseline, Week 24
Reported as:
Number · percentage
Percentage of Participants With Positive Anti-PAL-PEG IgE Antibodies
percentagerAvPAL-PEG
Baseline0
Week 240

Adverse events

Collected over Week 0- Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rAvPAL-PEG0/24 (0%)1/24 (4.2%)23/24 (95.8%)
Most frequent serious events
Most frequent serious events
EventrAvPAL-PEG
Blood creatine phosphokinase increasedInvestigations1/24
Most frequent other events
Showing 10 of 52
Most frequent other events
EventrAvPAL-PEG
Injection site reactionGeneral disorders18/24
ArthralgiaMusculoskeletal and connective tissue disorders18/24
Injection site erythemaGeneral disorders13/24
Injection site bruisingGeneral disorders10/24
Upper respiratory tract infectionInfections and infestations9/24
NauseaGastrointestinal disorders8/24
Injection site rashGeneral disorders8/24
RashSkin and subcutaneous tissue disorders8/24
HeadacheNervous system disorders7/24
PyrexiaGeneral disorders6/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)rAvPAL-PEG
Mean29.3 ± 11.43
Age, Customized
Age, Customized(Participants)rAvPAL-PEG
< 18 years1
> or = 18 years23
Sex: Female, Male
Sex: Female, Male(Participants)rAvPAL-PEG
Female13
Male11
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)rAvPAL-PEG
Hispanic or Latino0
Not Hispanic or Latino24
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)rAvPAL-PEG
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White24
Other0
Region of Enrollment
Region of Enrollment(Participants)rAvPAL-PEG
United States24
08

Study locations

6 sites
  • The Children's Hospital
    Aurora, Colorado 80048, United States
  • University of Florida, Gainesville
    Gainesville, Florida 32610, United States
  • Children's Hospital Boston
    Boston, Massachusetts 02115, United States
  • Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Albany Medical Center
    Albany, New York 12208, United States
  • University of Utah Hospital
    Salt Lake City, Utah 84132, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Sep 2013 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2019, 5 years 5 months after primary completion. A results delay was requested in Aug 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2012
First posted
Mar 22, 2012
Start
May 2012
Primary completionActual
Sep 2013
CompletionActual
Jul 2015
Results delay requested
Aug 17, 2017
Results first posted
Feb 27, 2019
Last update
Aug 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01560286
Responsible party
Sponsor
First posted
Mar 22, 2012
Start date
May 2012
Primary completion
Sep 2013
Completion
Jul 2015
Results posted
Feb 27, 2019
Last update
Aug 6, 2019

Study contacts

Debra Lounsbury
study director · BioMarin Pharmaceutical

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegvaliase

Start the discussion